• / Free eNewsletters & Magazine
  • / My Account
Home>Search Results

Related Content

  1. Videos
  2. Articles
  1. Our Top Five Biotech Takeout Picks

    Health-care analyst Lauren Migliore looks at what makes a biotech firm a likely takeout candidate and reveals our top five biotech M&A picks for 2010.

  2. What Does the Merger With NYSE Mean for ICE's Moat?

    Morningstar's Gaston Ceron addresses the short- and long-term prospects for and opportunities in ICE's takeover of NYSE Euronext.

  3. Top Biotech Acquisition Candidates

    2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.

  4. No Sign of Slowdown in Biotech M&A

    High levels of merger and acquisition activity will be the big theme of year for biotech, says Morningstar's Lauren Migliore.

  1. Cole Credit shareholders seek to block internal merger

    The battle over Cole III has taken a new twist, as shareholders sued to block the REIT's internal merger. Meanwhile, suitor American Realty Capital waits in the wings.

  2. Wells Fargo Advantage Has Cleaned House, but a Few Cobwebs Remain

    The firm's many mergers have yielded some good funds, though beware the price tags.

  3. 3 Cheap Stocks With Great Management

    These management teams should be good stewards of shareholder capital in today's uncertain environment.

  4. The Takeaway: Client acquisition costs the silent killer

     

1
ShareEmail
Print
Text Size
Comment
blog comments powered by Disqus
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.